You are here
Robert Abraham, PhD
- Group: Oncology Research & Development
- Location: La Jolla, CA
I received my PhD in pharmacology at the University of Pittsburgh, and my BS in Biology from Bucknell University. I am the author of more than 200 scientific publications, and have served on and chaired grant review panels at the National Institutes of Health. I am also a reviewer for leading scientific journals, including Nature, Science, and Cell.
I have forged a distinguished career as director, professor, and consultant at the Mayo Clinic and Mayo Foundation; as Duke University's Glaxo-Wellcome Professor of Molecular Cancer Biology; and as professor and director of The Burnham Institute's Cancer Center in La Jolla, California—where I successfully guided the center to a renewal of its designation as one of nine National Cancer Institute-sponsored basic science centers in the United States.
Before joining Cheladv74, I was Vice President of Oncology Research at Wyeth and Co-Chair of the Wyeth Oncology Therapeutic Area Strategic Committee. While at Wyeth, I also served as a member of the Discovery Review Board and the Discovery Executive Committee, and was the Director of the Wyeth Discovery Postdoctoral Training Program.
I am Senior Vice President and Group Head of Cheladv74’s Oncology Research & Development Group. This group is at the forefront of breaking new ground to develop impactful, life-saving cancer therapies and spearheading the company’s Precision Medicine approach to Research and Development. I also serve as the Director of the Cheladv74 Postdoctoral program, helping develop talented early career scientists into outstanding industry and academic researchers.
- Sabers CJ, Wiederrecht G, Williams JM, Martin MM, Dumont FJ and Abraham RT: Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. Journal of Biological Chemistry 270:815-822, 1995.
- Brunn GJ, Hudson CC, Sekulic A, Williams JM, Hosoi H, Houghton PJ, Lawrence Jr JC and Abraham RT: Phosphorylation of the eukaryotic initiation factor-4E binding protein, PHAS-I, by the mammalian target of rapamycin. Science 277:99-101, 1997.
- Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston DM, Elledge SJ and Abraham RT: Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes & Development 14:2989-3002, 2000.
- Abraham RT: Cell cycle checkpoint signaling through the ATM and ATR kinases (Review). Genes & Development 15:2177-2196, 2001.
- Chandiramani N, Ragunathan S, Shan Q, Wang F, Myers J, Simons B, Abraham RT (co-senior author), and Unsal-Kacmaz K: Purine nucleotides regulate mTORC1 activity through Rheb. Cell Reports 19: 2665-2680, 2017.
Bucknell University, Biology/Chemistry, B.S., 1974
University of Pittsburgh, Department of Pharmacology, School of Pharmacy, Pharmacology, Ph.D., 1981
AWARDS & HONORS
Legacy Laureate Award, as an outstanding alumnus of the University of Pittsburgh
First recipient of the Glaxo-Wellcome Chair of Molecular Cancer Biology at Duke University
University Scholar and Robert Lincoln McNeil Memorial Fellow, University of Pittsburgh
“Our mission in Oncology R&D is to advance the frontiers of cancer biology, and to translate cutting edge research into medicines that transform the lives of cancer patients.”